18
Jun
2020
Merck Wins 2 Big Approvals, a Surprise from Old ‘Dex,’ and a Digital Therapeutics First
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jun
2020
A Busy IPO Calendar: Forma, Repare, Progenity, Genetron
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Jun
2020
DNA Sequencing Startups Aim to Reduce Cost, Increase Meaning in the Data
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
Jun
2020
A Conversation About Race: Ted Love on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jun
2020
AstraZeneca Opens Its Digital Komono
AstraZeneca has emerged with a reputation as one of the industry’s most imaginative pharmas – it was named the “most innovative” global pharma company by IDEA Pharma in November 2019, and was cast as Gallant to GSK’s Goofus in a recent Financial Times piece examining their contrasting trajectories. In this context, I was especially excited when I saw what looked... Read More
11
Jun
2020
Inconvenient Truths and Rays of Light
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jun
2020
Fighting COVID-19 & Racism: Andy Plump on The Long Run
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jun
2020
Making Drugs at the Edge of Reason
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Jun
2020
Let’s Turn the Black Nod Into a Collective Nod
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jun
2020
Versant Bets $50M on Lycia to Make Protein Degraders Against Extracellular Targets
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Jun
2020
Complexity in Motion: Multi-Omics Tools Unravel Path From Genotype to Phenotype
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2020
Atlas Venture Closes Fund XII at $400 Million, Promotes Gladstone to Partner
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Jun
2020
Accent CEO Shakti Narayan on Targeting RNA-Modifying Proteins for Cancer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
5
Jun
2020
Tech Integration Into Pharma: A Report From The Front Line
Most biopharma companies can talk at some length about embracing data science, and sometimes it’s hard to get beneath the surface of what they’re doing, at least publicly. But it was my privilege recently to frame and moderate a very insightful recent conversation – recorded for on-demand viewing at this year’s virtual BIO 2020 conference. This provided an unusual opportunity... Read More
4
Jun
2020
Anger, Pain, and Hope
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Jun
2020
Digital Natives and Skilled Operators: Weaving Data Science Into Pharma R&D
An abiding challenge at the intersection of technology and pharma R&D is the need to bring together two historically disparate cultures. Tech companies tend to be led by engineers. Pharma R&D is generally run by chemists and biologists in the early stages, and by physicians further on in development. Each of these domains has its own distinct language, culture and... Read More
2
Jun
2020
Puretech Focuses on the Long-Term Lung Complications in COVID-19 Survivors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
May
2020
Biopharma Can Dig Deep and Fight Hard Against Injustice. Here’s How
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
31
May
2020
Adtech Data For Health: Time To Get Past The ‘Ick’ Factor
If you were responsible for the health of a large population, and could access just one of the following types of data, what would you choose (assuming all were acquired legally and responsibly)? (a) Genetics and other –omics data; (b) EHR data; (c) Consumer/adtech data. For at least the last 20 years, we’ve been obsessively focused on the first two... Read More
28
May
2020
The Infodemic Summer
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.